Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Nakano, M., Niizeki, T., Nagamatsu, H., Tanaka, M., Kuromatsu, R., Satani, M., et al. (2017) Clinical Effects and Safety of Intra-Arterial Infusion Therapy of Cisplatin Suspension in Lipiodol Combined with 5-Fluorouracil versus Sorafenib, for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion without Extra-Hepatic Spread: A Prospective Cohort Study. Molecular and Clinical Oncology, 7, 1013-1020.
https://doi.org/10.3892/mco.2017.1442

has been cited by the following article:

  • TITLE: Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

    AUTHORS: Junyi Shi, Ai Shen, Tong Mou, Zhongjun Wu

    KEYWORDS: Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis, Hepatic Arterial Infusion Chemotherapy

    JOURNAL NAME: Journal of Cancer Therapy, Vol.11 No.3, March 6, 2020

    ABSTRACT: The prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is very poor although sorafenib is recommended as the first-line treatment. Therefore, an effective treatment regime is needed for treating HCC with PVTT. This review summarized seven potential treatment regimes which including transarterial chemoembolization (TACE), TACE combined with sorafenib, TACE combined with radiotherapy (RT), hepatectomy, hepatic arterial infusion chemotherapy (HAIC), HAIC combined with sorafenib and HAIC combined with RT in the treatment of HCC with PVTT. In conclusion, hepatectomy or the combination of HAIC and sorafenib may be a more effective modality in the treatment of HCC patients with type I - II PVTT. HAIC combined with or without sorafenib/RT or the combination of RT and TACE is an alternative treatment choice for HCC patients with type III - IV PVTT. Further randomized controlled studies are warranted.